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Abstract
Objective. The aim of this study was to estimate the age at natural menopause in women with SLE.
Methods. One thousand and thirty-nine consecutive SLE patients <60 years of age were surveyed.
Demographic and clinical data were queried by a single investigator. SLE characteristics and co-morbid-
ities were retrieved from their medical records. Natural menopause was defined as amenorrhoea 512
months in the absence of previous hysterectomy, CYC exposure and severe chronic kidney disease
(SCKD). Pregnant women and those with menses during the 12 months prior to interview were considered
premenopausal. Median age at menopause was estimated by both logit and survival analyses. In addition,
mean age at menopause was calculated for patients aged 540 years. Factors associated with age at
natural menopause were assessed by Cox regression analysis.
Results. A total of 961 SLE women were analysed. At interview, most patients (81.6%) were premeno-
pausal, 7.9% had natural menopause, 6.3% were postmenopausal previously exposed to CYC, 4.1% had
undergone hysterectomy before menopause and 0.1% presented with SCKD and amenorrhoea. The mean
age at interview was 35.2 years (S.D. 10.1), the mean age at SLE diagnosis was 26.9 years (S.D. 8.6) and
the mean duration of disease was 8.2 years (S.D. 7.1). The mean recalled age at menopause was 46.4
years (S.D. 4.7). Median age at menopause estimated by logit and survival analyses were 50.7 and 50.8
years, respectively. Only the age at SLE diagnosis was associated with age at natural menopause.
Conclusion. Median age at natural menopause in women with lupus is 50 years. This is consistent with
the age at menopause reported in the general population.
Key words: systemic lupus erythematosus, age at menopause, risk factors, women’s health.
Introduction
Natural menopause is defined as the permanent cessation
of menstruation caused by the loss of ovarian follicular
activity. It corresponds to the last menstrual period
(LMP) and is recognized to have occurred after 12
consecutive months of amenorrhoea for which there is
no other obvious pathological or physiological cause [1].
The age at natural menopause seems to be determined
primarily by genetic factors, but some variability should be
observed [2]. Indeed, a number of studies have reported
differences in the timing of menopause experienced by
samples of women of different socio-economic, racial/
ethnic and lifestyle backgrounds [35]. Moreover, it has
long been believed that the menopause is presented at
a younger age in women suffering from autoimmune dis-
eases, including SLE [6].
As is well known, SLE is an autoimmune disease that
predominantly affects women, and although it generally
emerges during the reproductive ages, an increasing
number of patients are now reaching the age at which
natural menopause occurs [7, 8]. A few small studies
have suggested that the age at menopause in lupus pa-
tients is lower than that observed in the general
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population; however, whether the occurrence of meno-
pause at a younger age in lupus patients results from
the gonadotoxic effects of CYC treatment or from an auto-
immune-mediated ovarian injury is still being debated [9].
Besides its reproductive implications, the timing of
menopause is important since it is thought that it correl-
ates with the risk of cardiovascular disease, some gynae-
cological cancers, bone health and overall mortality. In
women with lupus, the increased risk of cardiovascular
disease and osteoporosis after menopause adds to the
risk associated with chronic inflammatory conditions
[10]. On the other hand, menopause has been related to
both lower lupus activity [11, 12] and greater damage ac-
crual of organs affected by individual flares [13]. Hence a
better understanding of the timing of natural menopause
and its determinant factors in the SLE population is rele-
vant, not only for improving counselling and health care
quality, but also to advance our knowledge regarding the
effects that SLE itself may exert on the ovaries. This study
is aimed at providing estimates of the mean and median
age at menopause in women with SLE, to show the ef-
fects of methodological choices on these age estimates
and to explore factors associated with the age at meno-
pause among SLE women.
Patients and methods
The study was approved by the Research Ethics
Committee (Comite´ de E´tica en Investigacio´n) of
Instituto Nacional de Ciencias Me´dicas y Nutricio´n
Salvador Zubira´n, Mexico City, Mexico, and all patients
gave their written informed consent before enrolment in
the study in accordance with the Declaration of Helsinki.
Enrolment was carried out over a 12-month period at our
outpatient rheumatology clinic. Consecutive patients with
a diagnosis of SLE according to the ACR criteria [14], <60
years old and attending their scheduled medical visit were
asked to participate in the survey. Women who were
unable to communicate by themselves were excluded.
A face-to-face interview that lasted 57 min was under-
taken by a single investigator (D.A.-R.) using a standar-
dized validated questionnaire. The questionnaire included
demographic characteristics (date of birth, years of edu-
cation and marital status), history of smoking (current and
past) and gynaecological data (age at menarche, pres-
ence of menstrual cycles, date of the most recent men-
strual period, parity, current pregnancy or breastfeeding,
use of contraceptives or menopausal hormone therapy in
the 3 months prior to the interview, history of hysterec-
tomy or tubal occlusion and their dates). Additional infor-
mation regarding treatment with prednisone, CYC, AZA,
MTX and antimalarials was also collected. In a second
step, each woman’s medical record was reviewed to de-
termine the precise date at diagnosis (when four criteria of
SLE were met), if SLE criteria presented at any time before
the interview, the date of first exposure to CYC and the
presence of other chronic diseases. Renal function was
assessed by either the CockcroftGault equation [15] or
the Modification of Diet in Renal Disease equation [16].
Finally, chronic damage accrual at the time of the
interview was estimated by a trained researcher using
the SLICC/ACR Damage Index (DI), with scores ranging
from 0 to 47 and higher scores corresponding to more
severe damage [17]. SLE disease activity was not
included in the survey data set because it is not system-
atically assessed in daily clinical practice. All information
was registered in standardized research forms to be
entered later into an electronic database.
Definitions used in the study
Premenopausal status was assigned to all women who
had regular or irregular menses during the 12 months
prior to the study or who were pregnant at the time of
the interview. Postmenopausal status was assigned to
women who fulfilled the definition of natural menopause.
Natural menopause was defined as amenorrhoea 512
months in the absence of previous hysterectomy, CYC
exposure or severe chronic kidney disease (SCKD).
Premature menopause was natural menopause at <40
years of age. Age at menopause was the age in years
calculated as the difference between the self-reported
LMP date and the patient’s birth date. Users of contra-
ceptive or menopausal hormone treatments were con-
sidered to be pre- or postmenopausal according to their
current menstrual pattern. Hysterectomy meant surgical
removal of the uterus, with or without oophorectomy.
Age at hysterectomy was the age in years calculated as
the difference between the self-reported date of surgery
and the patient’s birth date. CYC exposure was con-
sidered whenever the drug was administered, regardless
of its dose and route of administration. Age at first expos-
ure was the age in years calculated as difference between
the date of the registered first prescription and the pa-
tient’s birth date. SCKD was defined as creatinine clear-
ance <30 ml/min/1.73 m2 in at least two consecutive
measurements 6 months apart. Age at SCKD was the
age in years calculated as the difference between the
second creatinine clearance measurement and the pa-
tient’s birth date.
Statistical analysis
Descriptive statistics were used to summarize demo-
graphic and clinical characteristics.
Time at menopause was identified by both survey tech-
niques: self-recalled age at menopause and status at the
interview. Mean age at menopause was calculated with
ages obtained by self-recalled date at LMP in women
540 years of age, excluding those who had undergone
hysterectomy prior to the menopause, CYC treatment or
SCKD.
As described in several studies in the general popula-
tion, to arrive at the best estimate of age at menopause in
SLE women, median ages were calculated by logit and
KaplanMeier analyses. In the logit analysis the current
status approach was used to define age at menopause,
considering menopause status as the dependent variable
and the age at interview as the independent variable. The
median age at menopause was the point at which 50%
of women in the study population were postmenopausal
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[18, 19]. Patients with amenorrhoea 512 months, who
had previously had a hysterectomy, CYC exposure and/
or SCKD were excluded. Given that the age distribution of
the sampled population affects menopausal age estima-
tions, the analysis was repeated in a subgroup of women
540 years of age (which includes a larger proportion of
postmenopausal women).
The self-recalled date at LMP was used to compute the
median age at natural menopause by KaplanMeier ana-
lysis [20]. Amenorrhoeic women with hysterectomy, CYC
treatment or SCKD that preceded the menopause were
censored by the event that occurred first. Premenopausal
women were censored by interview date. The time vari-
able was age at censoring or LMP in natural menopause.
A modified KaplanMeier survival analysis [21, 22] was
also applied to the sample, considering four competing
event risks: natural menopause, hysterectomy, meno-
pause with previous CYC exposure and amenorrhoea
with SCKD. The competing risk model allows accurate
analyses of the distribution of age at menopause account-
ing for the effects of the other three risks. This analysis
was computed using the module cmprsk in R to calculate
the adjusted cumulative incidence estimates in the study
group [23, 24]. Lastly, the KaplanMeier analysis was re-
peated in a subgroup of patients settled by the principal
stratification method [25, 26]. For this stratification ana-
lysis we considered age at interview as an exposure
with three age groups: (i) <40 years, (ii) 540 to <50
years and (iii) 550 years. The median age at menopause
was assessed in the group of women 550 years of age
[group (iii)], who had remained free of hysterectomy, CYC
exposure and SCKD.
Cox regression analysis was used to explore causal re-
lationships between variables present before menopause
that do not change with time (age at menarche, parity,
tubal occlusion and age at SLE diagnosis) and the age
at menopause. Other collected covariates were not used
for this analysis because they were ascertained only at the
time of interview (i.e. smoking, education level, marital
status, SLICC/ACR DI and BMI). SPSS 21.0 (SPSS,
Chicago, IL, USA), STATA 11.0 (StataCorp, College
Station, TX, USA) and R 3.0.1 (R Foundation for
Statistical Computing) were used for the analyses.
Results
Of the 1039 patients who were interviewed, 78 were
excluded because they did not meet SLE diagnostic cri-
teria (n= 19), SLE ensued after they became postmeno-
pausal, underwent hysterectomy or were diagnosed with
SCKD (n= 54) or data were incomplete (n= 5), leaving 961
to be analysed.
Tables 1 and 2 summarize the principal demographic
and clinical characteristics of the study population. The
average age at interview was 35.2 years (S.D. 10.1) and
at SLE diagnosis was 26.9 years (S.D. 8.6). The mean
duration of disease was 8.2 years (S.D. 7.1). The mean
SLICC/ACR DI score in the study population was 0.9
(S.D. 1.4) and 42% of patients had a SLICC/ACR DI
score 51. Nearly one-third [n= 303 (31.5%)] of the
TABLE 2 Disease characteristics of women with SLE at
interview
SLE women
(n= 961)
Age at SLE diagnosis, mean (S.D.), years 26.9 (8.6)
Disease duration, mean (S.D.), years 8.2 (7.1)
Current prednisone treatment, n (%) 549 (57)
Prednisone dose, mean (S.D.), mg 12.9 (12.6)
CYC treatment ever, n (%) 303 (32)
Past CYC treatment, n (%) 259 (27)
Current oral CYC, n (%) 19 (2)
Current i.v. CYC, n (%) 25 (3)
SLICC/ACR DI score, mean (S.D.) 0.9 (1.4)
SLICC/ACR DI score 51, n (%) 406 (42)
SLICC/ACR DI scorea, mean (S.D.) 2.1 (1)
SCKD, n (%) 43 (5)
SLE criteria over time, n (%)
Malar rash 642 (67)
Discoid rash 112 (12)
Photosensitivity 530 (55)
Oral ulcers 569 (59)
Arthritis 841 (88)
Serositis 337 (35)
Renal disorder 436 (45)
Neurological disorder 132 (14)
Haematological disorder 865 (90)
Immunological disorder 884 (92)
Abnormal ANAs 833 (87)
SLICC/ACR DI: SLICC/ACR Damage Index (score range
047) [17]. Severe chronic kidney disease is defined as cre-
atinine clearance <30 ml/min/1.73 m2. aMean SLICC/ACR DI
score among patients with a score 51.
TABLE 1 Demographic features and gynaecological
characteristics of women with SLE at interview
SLE women
(n= 961)
Demographic features
Age, mean (S.D.), years 35.2 (10.1)
Education, mean (S.D.), years 12.6 (3.9)
Marital status, n (%)
Never married 459 (48)
Married/living as married 434 (45)
Divorced/separated/widowed 68 (7)
Current smoking, n (%) 95 (10)
Past smoking, n (%) 122 (13)
BMI, mean (S.D.), kg/m2 25.9 (5.0)
Gynaecological characteristics
Age at menarche, mean (S.D.), years 12.6 (1.5)
Number of pregnancies, mean (S.D.) 1.4 (1.6)
Current pregnancy, n (%) 17 (2)
Menses during the previous
12 months, n (%)
Present 784 (82)
Absent 177 (18)
Contraceptive method use, n (%) 169 (18)
Menopausal hormone therapy use, n (%) 24 (3)
History of tubal occlusion, n (%) 196 (20)
History of hysterectomy, n (%) 47 (5)
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patients had ever been exposed to CYC and 549 (57.1%)
were under prednisone treatment. At the time of interview
most patients were still menstruating [784 (81.6%)],
whereas 177 (18.4%) were amenorrhoeic. Among ame-
norrhoeic women, 76 (7.9%) had experienced menstrual
cessation via natural menopause (17 before the age of 40
years), 39 (4.1%) by hysterectomy, 61 (6.3%) after CYC
exposure and 1 (0.1%) due to SCKD.
Age at natural menopause
Table 3 summarizes the results of the estimations of age
at natural menopause. The mean recalled age at meno-
pause was 46.4 years (S.D. 4.7). The median age at meno-
pause computed by logit analysis was 50.7 years, quite
similar to the age of 50.5 years that resulted from the
analysis restricted to women 540 years of age (n= 309).
The median age calculated by the KaplanMeier survival
analysis was 50.8 years (S.E. 0.7); this figure was consist-
ent with that obtained by logit analysis. In survival ana-
lyses, 101 patients with amenorrhoea who did not fulfil the
criteria of natural menopause were censored: 39 by age at
hysterectomy, 61 by age at first exposure to CYC and 1 by
age at diagnosis of SCKD. Premenopausal patients
(n= 784) were censored by age at interview. When com-
peting risks were considered in the KaplanMeier ana-
lysis, the median age at natural menopause was 2.45
years later: 53.3 years (S.E. 0.1). At age 50 years the ad-
justed cumulative incidence was 0.32, therefore the cu-
mulative survival proportion by each age year was higher
across the analysis.
In the principal stratification analysis, the number of pa-
tients corresponding to the groups (i) <40 years, (ii) 540
to <50 years and (iii) 550 years were 652 (67.8%), 226
(23.5%) and 83 (8.7%), respectively. In group (iii) there
were 57 (69%) patients who remained free of events
such as hysterectomy, CYC exposure and SCKD. Forty-
five of these 57 women had undergone natural meno-
pause. The causal effect of age group (ii) vs age group
(i) was [(27/57) (4/57)] = 0.40 [the difference between
the risk of natural menopause in age group (ii) and age
group (i)]. Similarly, the causal effect of age group (iii) vs
age group (ii) was [(14/57) (27/57)] =0.22. The median
age at menopause among the patients free of events from
group (iii) was 49.7 years (S.E. 0.5). Fig. 1 depicts in a
boxplot the distributions of menopause ages by
KaplanMeier survival analysis with censoring, with com-
peting risk and in the group of women 550 years of age
from principal stratification analysis free of events.
Factors associated with age at menopause among
SLE women
Only age at SLE diagnosis was significantly associated
with age at natural menopause, with a relative risk of
0.97 (95% CI 0.94, 0.99), suggesting that older age at
SLE diagnosis is associated with a lower risk of meno-
pause. Parity, age at menarche and history of tubal occlu-
sion were not significantly associated with the age at
natural menopause. T
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Discussion
Herein we report on the results of a survey to estimate the
age at natural menopause among women with SLE and to
examine the factors associated with that. Since it has
been claimed that variations in the reported age at meno-
pause might depend on the procedure utilized for meas-
urement as well as on the age distribution of the sample,
we examined the age at menopause in patients with lupus
by applying different methodologies.
The mean recalled age at menopause in our study
group, 46.4 years, was within the range of those previ-
ously reported in SLE women [13, 20, 2729]; however,
valid comparisons cannot be made across studies due to
existing differences in patients’ conditions, protocol de-
signs and data analysis methods. Like in most studies
carried out in either clinic or population-based samples,
we used the median to better estimate the age at meno-
pause in women with lupus. To our knowledge this meas-
urement has not been made in samples of lupus patients;
therefore our study provides pioneering information on
this issue. Median age at menopause obtained by either
logit or survival analysis in our SLE population was similar
and in line with that obtained in the subgroup of patients
who had reached the age of 50 years remaining free of
hysterectomy, CYC exposure and SCKD (50.8, 50.7 and
49.6 years, respectively). Only when competing event
risks were taken into account did the median estimation
shift to 53.5 years, which means 2.5 years later than the
median calculated by the survival analysis with censoring.
This finding might reflect the influence that hysterectomy,
CYC exposure and SCKD exert on the hazard of natural
menopause in SLE patients.
Our results cannot be compared with others because
no similar studies in lupus patients are available in the
literature. Neither can they be compared with estimations
of the age at menopause in the general population be-
cause a control group was not included in the study
design. However, it should be noted that our findings
are consistent with results of previous research on the
age at menopause in samples of Mexican women without
lupus. Indeed, utilizing logit or probit analysis, the median
age at menopause found in a number of Mexican studies
ranged from 48.2 to 49.7 years [3033]. On the other hand,
the median age at menopause computed by survival ana-
lysis among women participating as controls in a multina-
tional study by the World Health Organization was 51
years [34] and that found in the population-based investi-
gation carried out in Puebla, Mexico, was 50 years [32].
Natural premature menopause was identified in 1.7%
of surveyed patients. Elucidation of the mechanisms
underlying the premature cessation of ovarian function in
these individuals is beyond the scope of this study and
deserves future investigation. In our patient sample, only
older age at SLE diagnosis was associated with a lower
risk of menopause. Parity, age at menarche and a history
of tubal occlusion have not been clearly described as fac-
tors associated with age at natural menopause in the gen-
eral population either [35].
We should recognize several limitations and strengths
of our investigation. The principal limitation relies on the
cross-sectional design, since it is agreed that better as-
sessments of the age at menopause and its related fac-
tors can be obtained with a longitudinal design. As in other
studies, a methodological concern is that amenorrhoea
>12 months was taken as synonymous with menopause.
Thus patients with reversible amenorrhoea, unrelated to
ovarian failure, could have been misclassified. Such is the
case of women receiving progestin-only contraceptives,
danazol and perhaps high doses of prednisone; however,
all these scenarios would shift the median age at meno-
pause towards a lower rather than a higher estimate. On
the other hand, patients receiving either combined contra-
ceptives or menopausal hormone treatment could also be
misclassified. Oestrogen-containing formulations induce
endometrial bleeding or menstruation that can mask nat-
ural menopause. In these cases the median age at meno-
pause would be shifted towards a higher estimate. We did
not attempt to identify patients with natural menopause
under hormonal treatment because the collected data
referred only to the use of unspecified hormonal treat-
ments over the 3 months prior to the interview. In this
survey it was not possible to gather useful information
about SLE activity and chronic damage accrual prior to
menopause. Hence inferences on how disease activity
and the severity of chronic damage may impact the age
at menopause cannot be made. Repeated measures of
FIG. 1 Distribution of age at natural menopause among
women with SLE
Boxplot shows median age at menopause estimated by
different survival analyses: with censoring, with competing
risks and in the group of women who reached the age of
50 years without having had hysterectomy, CYC exposure
or severe chronic kidney disease (from the principal
stratification analysis). The median age is depicted by the
centre line of the box and the interquartile range (distance
from the 25th to 75th percentiles) by the length of the box.
The dotted lines extending from the top and bottom of the
box represent the extreme values of the data.
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SLE activity within a longitudinal design would be neces-
sary to explore these important relationships. Lastly, the
lack of a control group precludes valid comparisons of the
age at menopause between SLE patients and women in
the general population.
Among the strengths are that all patients belonged to
similar racial/ethnic groups, were studied and treated in
the same institution (under uniform criteria) and were inter-
viewed by a single investigator. All definitions employed in
the survey were previously defined and are widely ac-
cepted. Since both CYC treatment and SCKD are
known causes of amenorrhoea [3537], non-menstruating
patients who had been exposed to these before natural
menopause were excluded or censored in the analyses.
On the other hand, menstruating patients ever exposed to
CYC or SCKD remained in the study and were analysed.
Even though our study population reflects a wide spec-
trum of lupus, our data may not be generalized to other
lupus patient populations because ethnic and sociocul-
tural conditions have been associated with variations in
the age at menopause.
In conclusion, the median age at menopause among
women with SLE is estimated at 50 years. This is con-
sistent with the age at menopause reported in the general
population and suggests that the physiological mechan-
isms responsible for ovarian ageing seem to be preserved
in most SLE women.
Rheumatology key messages
. This study provides pioneering information on age
at natural menopause in women with SLE.
. Applying strict methodology, age at natural meno-
pause in SLE is consistent with that reported in the
general population.
. This research suggests that the physiological mech-
anisms responsible for ovarian ageing are pre-
served in most SLE patients.
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